Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several administration/self-injection and safety-related claims are supported (route/device forms; patient/caregiver self-administration after training; risks of injection site reactions and hypersensitivity; medication errors). However, multiple claims are either inaccurate relative to the provided label excerpts (in particular: thigh/abdomen injection-site specifics and patient vs healthcare-provider self-administration wording) or not directly supported (e.g., IL-17A targeting wording, cost-effectiveness/convenience, and broad allergic-reaction severity range). Material pediatric self-administration restriction is also not consistently reflected.
Category Scores
Accurate Statements
Cosentyx (secukinumab) is a biologic medication used to treat autoimmune diseases including psoriasis, psoriatic arthritis, and ankylosing spondylitis.
Label sections 1.1 (plaque psoriasis), 1.2 (psoriatic arthritis), and 1.3 (ankylosing spondylitis) list these indications for COSENTYX; formulation as a biologic and the term 'autoimmune diseases' are not explicitly stated in provided excerpts.
Cosentyx is a monoclonal antibody that targets interleukin-17A (IL-17A).
The provided excerpts include 'IL-17 inhibitors including COSENTYX' but do not explicitly state 'monoclonal antibody' or 'targets IL-17A' in the quoted label text.
Cosentyx is administered using a prefilled syringe or pen.
Section 2.2: 'UnoReady pen, Sensoready pen, and prefilled syringes are for subcutaneous use only.'
The recommended dosage and administration schedule of Cosentyx vary depending on the specific condition being treated.
Section 2.3 (PsO), 2.4 (PsA), 2.6 (AS), 2.8 (nr-axSpA), and 2.10 (HS) provide different dosing regimens by condition.
Cosentyx can be administered subcutaneously (under the skin) by a healthcare provider.
Section 2.2: 'COSENTYX is for use under the guidance and supervision of a healthcare provider' and subcutaneous use is specified for pen/prefilled syringes.
Cosentyx can be administered subcutaneously by the patient themselves if they have been trained to do so.
Section 2.2: 'Adult patients may self-administer COSENTYX or be injected by a caregiver after proper training…'
Proper self-administration of Cosentyx requires training and support from a healthcare provider.
Section 2.2: adult self-administration is allowed 'after proper training' and 'under the guidance and supervision of a healthcare provider.'
Patients should receive instruction on proper injection technique for self-administration of Cosentyx.
Section 2.2: adult caregiver/patient self-administration 'after proper training' and includes instruction/preparation concepts (exact wording 'injection technique' is not quoted, but training is required).
Patients should receive guidance on the dosage and administration schedule for self-administration of Cosentyx.
Label contains condition-specific recommended dosages and states guidance/supervision with self-administration after proper training (Sections 2.2 and 2.3-2.10).
Medication errors may occur with self-administration of Cosentyx, including administering the wrong dose or frequency.
The provided excerpts do not explicitly mention medication errors or wrong dose/frequency in section text shown.
Patients with a history of injection site reactions should consult with their healthcare provider before self-administering Cosentyx.
The provided excerpts mention only injection-related adverse events generally (e.g., 'eczema eruptions', hypersensitivity) but do not specifically address 'injection site reactions' counseling; thus support is incomplete in provided text.
Patients with a history of allergic reactions should consult with their healthcare provider before self-administering Cosentyx.
Label includes serious hypersensitivity reactions and instruction to discontinue if serious allergic reaction occurs (Section 5.2), but does not explicitly provide 'consult before self-administering' wording in provided excerpts.
Unsupported Statements
Cosentyx is administered via injection into the thigh or abdomen.
Provided label excerpts specify subcutaneous use (Section 2.2) but do not specify injection sites such as thigh or abdomen.
Cosentyx is a monoclonal antibody that targets interleukin-17A (IL-17A).
Provided excerpts mention 'IL-17 inhibitors including COSENTYX' (Section 5.1) but do not explicitly state it is a monoclonal antibody or that it targets IL-17A.
Self-administration of Cosentyx at home may result in injection site reactions including redness, swelling, or itching.
Provided excerpts do not list injection site reaction details (redness/swelling/itching) for self-administration.
Self-administration of Cosentyx at home may result in allergic reactions ranging from mild to severe.
Provided excerpts include serious hypersensitivity reactions (Section 5.2) and contraindication for previous serious hypersensitivity, but do not describe a mild-to-severe range in the quoted text.
Medication errors may occur with self-administration of Cosentyx, including administering the wrong dose or frequency.
No medication error content is present in the provided label excerpts.
Self-administration of Cosentyx may be a convenient option for patients.
No 'convenient' claim appears in provided label excerpts.
Self-administration of Cosentyx may be a cost-effective option for patients.
No cost-effectiveness claim appears in provided label excerpts.
Patients with a history of injection site reactions should consult with their healthcare provider before self-administering Cosentyx.
Provided excerpts do not contain guidance specifically tied to prior injection site reactions and self-administration.
Patients with a history of allergic reactions should consult with their healthcare provider before self-administering Cosentyx.
Provided excerpts state hypersensitivity reactions and 'immediately discontinue' if serious reaction occurs, but do not provide the specific counseling phrasing about consulting before self-administration.
Contradictions
Low
AI Statement
Cosentyx can be administered subcutaneously by the patient themselves if they have been trained to do so.
Label Reference
Section 2.2: 'Pediatric patients should not self-administer COSENTYX. An adult caregiver should prepare and inject COSENTYX after proper training…'
Important Omissions
Boxed warning status (if any) and whether COSENTYX has one are not addressed. The provided label excerpts do not show a boxed warning section.
Importance:
Moderate
Key pre-treatment and ongoing safety evaluations (e.g., TB evaluation and vaccinations; IBD caution) are not included despite being central label requirements for initiating therapy.
Importance:
Moderate
Serious adverse events beyond injection-site/allergic reactions are not covered (e.g., opportunistic infections, TB, IBD exacerbation, latex sensitivity).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Some claims are unsupported or partially supported (e.g., injection site specifics, IL-17A targeting wording, injection-site reaction details, medication error and mild-to-severe allergy range, convenience/cost-effectiveness). Additionally, pediatric self-administration restriction is not reflected, which could mislead if applied broadly.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple statements are not supported by the provided label excerpts (notably injection-site specifics, IL-17A/monoclonal antibody wording, detailed injection site/allergy severity descriptions, medication error, convenience/cost-effectiveness), and pediatric self-administration prohibition is not stated.
Suggested Improvement
Limit administration and safety statements to what the label excerpts support: cite subcutaneous use with pens/prefilled syringes, training requirements, and explicitly note that pediatric patients should not self-administer. Remove unsupported specifics (thigh/abdomen; injection-site reaction details; mild-to-severe allergy range; medication error examples; convenience/cost-effectiveness) unless supported by additional label text.